共 50 条
- [41] Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal PharmacoEconomics, 2019, 37 : 1195 - 1207
- [43] Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal PharmacoEconomics, 2020, 38 : 527 - 536
- [44] Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal PharmacoEconomics, 2019, 37 : 131 - 139
- [49] Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal PharmacoEconomics, 2018, 36 : 1143 - 1151
- [50] Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal PharmacoEconomics, 2018, 36 : 917 - 927